A Case of Elderly Type 2 Diabetes Developing Fournier's Gangrene While Taking Dapagliflozin

DOI
  • Imaishi Nao
    Department of Diabetes, Metabolism and Endocrinology, Koseiren Tsurumi Hospital
  • Hidaka Shuji
    Department of Diabetes, Metabolism and Endocrinology, Koseiren Tsurumi Hospital
  • Uchida Hiroki
    Department of Gastrointestinal Surgery, Koseiren Tsurumi Hospital
  • Shono Tomoko
    Department of Dermatology, Oita University
  • Nakamura Yusuke
    Department of Dermatology, Oita University
  • Uehara Miyuki
    Department of Plastic Surgery, Oita University
  • Shimizu Fumiaki
    Department of Plastic Surgery, Oita University
  • Goto Mizuki
    Department of Dermatology, Oita University
  • Hatano Yutaka
    Department of Dermatology, Oita University
  • Tawara Yasuko
    Department of Diabetes, Metabolism and Endocrinology, Koseiren Tsurumi Hospital
  • Shimasaki Takanobu
    Department of Diabetes, Metabolism and Endocrinology, Koseiren Tsurumi Hospital
  • Shibata Hirotaka
    Department of Endocrinology, Metabolism, Rheumatology and Nephrology, Faculty of Medicine, Oita University

Bibliographic Information

Other Title
  • SGLT2阻害薬（ダパグリフロジン）を服用中にフルニエ壊疽を発症した高齢2型糖尿病の1例

Description

<p>The patient was a 74-year-old woman with type 2 diabetes that had been diagnosed when she was 56 years of age. In early May, she visited a dermatologist due to pain in the left gluteal region, but the antibiotics that she was prescribed did not alleviate this symptom. She had been taking dapagliflozin since mid-October of the previous year. In mid-May, she was discovered after a fall and was transferred to our hospital. Her body temperature was 38.6 °C. Severe inflammation was evident from redness in the region of the left side of the anus and perineum, a white blood cell count of 17200 /μL, and a C-reactive protein level of 29.7 mg/mL. A finding of gas within the subcutaneous fat on the left perineum on computed tomography led to a diagnosis of Fournier's gangrene (FG), and the patient was subsequently transferred to the Department of Dermatology at Oita University. Emergency incision and debridement with multidisciplinary therapy saved her life. In August 2018, the US Food and Drug Administration issued safety information about an increased risk of FG in patients on SGLT2 inhibitors (SGLT2i). We encountered a patient who developed FG while on an SGLT2i and report this case as a warning about the use of SGLT2i.</p>

Journal

Related Projects

See more

Keywords

Details 詳細情報について

  • CRID
    1390845713084313856
  • NII Article ID
    130007684566
  • DOI
    10.11213/tonyobyo.62.389
  • ISSN
    1881588X
    0021437X
  • Text Lang
    ja
  • Article Type
    journal article
  • Data Source
    • JaLC
    • CiNii Articles
    • KAKEN
  • Abstract License Flag
    Disallowed

Report a problem

Back to top